MDCO +6%/PM on (purportedly) positive phase-2 PCSK9 data from ORION-1 study: http://finance.yahoo.com/news/medicines-company-announces-positive-top-111500147.html The interim analysis of Day 90 follow-up for all 501 patients, as well as top-line data from Day 180 follow-up for up to 200 patients, will be presented in a Late-Breaking Clinical Trials session at the AHA Scientific Sessions 2016 on November 15, 2016 in New Orleans. No actual data were released in today’s PR.